Deborah loved geeky science and she would have been so proud of Bowelbabe lab, say family as unit is named in her honour
Last week the Stem Cell and Cancer Biology Lab at the Francis Crick Institute, near King's Cross station in London, was officially renamed The Bowelbabe Laboratory in her honour.
8
Dame Deborah James' nickname is now etched on the door of one of Britain's leading cancer research labs
Credit: instagram/bowelbabe
8
TV's Deborah died of bowel cancer in 2022
Credit: Instagram
Her brother Ben and sister Sarah Wieczorek took part in Sunday's London Marathon, both dressed as a poo, to raise money for the Bowelbabe Fund.
Ben, 34, told The Sun: 'Debs loved geeky science, especially this project where they are growing organoids and mini bowels.
'Whether it's cutting-edge research into personalised medicine or early detection, she loved it and she wanted to set up this fund to do exactly this.'
And Debs' husband, Seb Bowen told how she would have been 'unbelievably proud' to see the impact her Fund is having.
'Exciting but bittersweet'
He said: 'I felt so many emotions, but the overwhelming one was a sense of enormous pride at Deborah's fund being a part of this amazing, world-class institution.'
Sun columnist Dame Debs died from bowel cancer aged just 40 in 2022 but not before starting a massive charity and awareness movement to help save others from suffering the same fate.
Cash from her £17million legacy Bowelbabe Fund is now paying scientists on the frontline of bowel cancer research.
They are growing tiny organs in petri dishes and conducting DNA analysis to work out how to catch and treat the devastating disease.
The Sun joined Debs' family last week for a tour of the facility with researchers, Cancer Research UK and the Health Secretary Wes Streeting.
Ben added: 'We've all enjoyed learning the science side of things. Like many families, you get into it when you are impacted by it.
Sun Health Explainer: Bowel Cancer
'Debs was fortunate enough to be with us for five years plus because of some of this research, and during that time she brought us into the loop and kept beating the drum for better awareness and understanding.
'It is always bittersweet but it's really exciting for the family to see that the money generously donated by the public is going to great use.'
Bowel cancer is one of the most common types of tumour in the UK and the second biggest cancer killer.
Around 17,000 Brits die from the disease each year, fewer only than lung cancer which claims 35,000 lives.
Half of cases could be prevented with healthier living but many are harder to explain.
Scientists are particularly worried that the disease is becoming more common in young adults such as Debs, who was diagnosed aged just 35.
Michelle Mitchell, chief executive of Cancer Research UK, said: 'Bowel cancer research is a significant priority for us. We are seeing a dramatic in- crease in early onset cancer around the world. We don't exactly know why yet, but that's why more research is absolutely critical.'
Dr Ian Walker, director of policy at the charity, added: 'The key thing for us is that we know if you detect bowel cancers early you have a significant change in your prognosis.
'Patients detected with very early stage bowel cancer have 90-plus per cent survival after five years.
'Whereas if you detect bowel cancer in the later stage of stage four that can be around only ten per cent.'
Scientists working in the Bowelbabe lab, led by Dr Vivian Li, are studying early warning proteins in at-risk patients.
They hope to be able to detect chemical signals in blood or poo samples that could help with faster diagnosis of less common tumours.
Analysing genes that appear only in people with cancer could also help to develop early warning signs and provide targets for treatment.
A big focus for the team is the issue of chemotherapy resistance.
This occurs when treatment stops working because a tumour gets used to the drugs being used to attack it.
8
Debs' brother Ben poses next to the lab sign
Credit: Simon Jones
8
Health Sec Wes Streeting meets Debs' parents Heather and Alistair
Credit: Simon Jones
Dr Li estimates this happens eventually in 90 per cent of patients with stage four cancer that has spread.
She told The Sun: 'One of our recent findings is a gene called SOX2, which potentially contributes to chemotherapy resistance.
'That gene drives the cancer cell to go to sleep and the chemotherapy does not work on sleeping cells — it can only kill the cancer when the cells are dividing. Then when you withdraw the drug the cells can grow again.
'Now we're trying to revert that to sensitise the patient to chemotherapy.'
Dr Li's lab is also trying new approaches to immunotherapy, which harnesses the body's own immune system to attack cancer cells.
They are able to test new treatment methods or genetic therapies on fascinating organoids in the lab.
Organoids are tiny human organs or tumours grown in petri dishes using cells harvested from patients.
They react just like the cells in the body parts doctors want to target, meaning researchers can test how different approaches might work in the clinic.
'Pushing the frontiers'
Supporting Dr Li's project was a no-brainer for Debs' family.
Towards the end of her life, Dame Debs had an organoid of her own bowel tumour created, at the Institute of Cancer Research in London.
Deborah would've shared my pride, she would've found it all really, really exciting
Seb Bowen
She was also a regular visitor to laboratories including those at The Crick where she helped lift the curtain on the cutting-edge science giving so many cancer patients hope.
After being diagnosed in 2016, the former deputy head teacher made it her mission to raise awareness, dressing up in poo emojis to break taboos and urging people: 'Check your poo!'
FUND HIT £17M
THE BowelBabe Fund was set up in May 2022 after Debs revealed in her final Sun column she had returned to her parents' home to receive palliative care.
Dame Deborah made a final plea for people to help her hit £10million and, since her death, the fund soared to £17million.
The cash has funded projects – including a new X-ray machine at the Royal Marsden Hospital in Surrey, where she was treated, and a bowel cancer roadshow to raise awareness.
Most of the money is funding cutting edge cancer research, including new treatments, better testing, using AI for diagnosis and understanding how tumours spread. If you would like to donate go to bowelbabe.org
She shared the signs and symptoms every one should know in her Sun column, Things Cancer Made Me Say, and called for action to invest in research to find new treatments.
Deborah often said she was 'riding on the wings of science' — a reference to the fact new, cutting-edge treatments helped her survive for five-and-a-half years, when statistics suggested she might not live a year.
So seeing her name adorned on the door of a lab at The Crick was such a special moment for her family.
Her parents Heather and Alistair, told The Sun: 'Deborah would be over the moon to know that a lab dedicated to finding new treatments bears her name.'
8
Ben, centre, and Seb Bowen meet Wes at the lab
Credit: Simon Jones
Seb added: 'With talented scientists from around the world and CRUK, the UK is at the forefront of cancer research, and I'm not sure many people realise that.
'Deborah would've shared my pride, she would've found it all really, really exciting.
'To see money raised in her name helping fund projects that will hopefully one day help save lives, was exactly what she hoped for.
'It's inspiring to know the fund has the potential to have such a positive impact.'
One of the reasons Dame Deborah's legacy is so impactful is that every time she's in The Sun or in the media, we see searches for bowel cancer symptoms going up and people going and getting tested
Wes Streeting
Her parents added: 'Deborah didn't want us all sitting around feeling sad, and in setting up the Bowelbabe Fund she ensured that we always have a really positive focus.
'She has, and continues to be, at the forefront of our minds when we decide on the projects to support — made easier by the fact we all know what she would've wanted. To know that she is still helping to save lives almost three years on, makes us all very proud.'
Wes Streeting, a cancer survivor himself, visited the lab last week with Debs' family.
He said: 'One of the reasons Dame Deborah's legacy is so impactful is that every time she's in The Sun or in the media, we see searches for bowel cancer symptoms going up and people going and getting tested.
'The work that is now being done in her name and the fundraising that has taken place in her name — thanks to her amazing family — is pushing the frontiers of medical science in this area.
'That legacy lives on so it's entirely fitting that we've now got the Bowelbabe Lab here with Cancer Research UK at the Crick Institute.'
8
Debs' husband, Seb told how she would've been 'unbelievably proud' to see the impact her Fund is having
Credit: Getty
8
Deborah's nickname on the laboratory window
Credit: Simon Jones
8
Ben with sister Sarah after running Sunday's London Marathon
Credit: Supplied
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
an hour ago
- Scottish Sun
‘Remarkable' new vaccine shown to slow down world's deadliest cancer in move to ‘beat cancer for everyone'
Cancer patients survived around two years and five months after receiving the new jab FRESH HOPE 'Remarkable' new vaccine shown to slow down world's deadliest cancer in move to 'beat cancer for everyone' Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) THOUSANDS of Brits with cancer have been given fresh hope as a new jab could slow down the disease and boost survival. The vaccine, described as "remarkable" by scientists, has shown promising results in the fight against one of the deadliest forms of the disease - pancreatic cancer. Sign up for Scottish Sun newsletter Sign up 1 The new jab trains the immune system to attack mutated genes found in many pancreatic and bowel cancers Credit: Getty - Contributor Early trials have proven the jab's ability to supercharge the immune system, enabling it to attack cancer cells and potentially prolong life for patients. More trials are now underway among a larger group of pancreatic and bowel cancer patients, as experts warn it is "too early" to say whether the jab will work at scale. Pancreatic cancer, which affects around 10,000 Brits each year, is the deadliest cancer in the world. And only about seven out of 100 of them will survive it for five years or more, according to Cancer Research UK. This is partly because it shows no symptoms until it has already spread to other parts of the body, making it incredibly hard to treat. While surgery, chemotherapy and radiation can help extend life, they rarely offer a cure. But researchers are now optimistic that this new vaccine could change that, providing a vital new treatment option other therapies fall short. 'Our results show that in the group of patients who had profound immune responses 68 per cent) we saw longer survival than we have expected in this cancer,' said Dr Zev Wainberg, study lead from the University of California, Los Angeles. 'Quite a remarkable finding to occur in a phase 1 trial.' The jab targets a mutated gene called KRAS, which is found in many pancreatic and bowel cancers. I'm a doctor, NEVER ignore these pancreatic cancer symptoms It's a type of immunotherapy vaccine designed to improve the immune system's ability to fight cancer by delivering the vaccine directly to the lymph nodes, which play a crucial role in immune defence. In the phase 1 trial, 20 pancreatic cancer patients and five bowel cancer patients received the vaccine. After 20 months, 68 per cent of patients developed strong immune responses. On average, the pancreatic cancer patients survived around two years and five months after receiving the vaccine, according to the study published in Nature Medicine. 'Patients with the strongest immune responses lived longer and stayed cancer-free for more than 15 months,' Dr Zev added. While some cancer jabs are personalised to each patient, this jab, ELI-002 2P, has a single version which can be given to all patients. This "off-the-shelf" version means that it can be manufactured in bulk and given more rapidly. Dr Chris Macdonald, head of research at Pancreatic Cancer UK, said: 'This study is a big step forward in treating pancreatic cancer. "The 'off-the-shelf' vaccine approach is quicker, cheaper, and could help many more people.' The study has already led to a phase 2 trial with 144 pancreatic and bowel cancer patients, with results expected in the coming months. Dr Dani Edmunds, research information manager at Cancer Research UK, added: "Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat. "Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer. "The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment. "These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination. "Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine. "More research is needed to understand why some people benefit from the vaccine while others don't so that we can make sure we're beating cancer for everyone." Dr Magnus Dillon, an oncologist at The Royal Marsden NHS Foundation Trust, said: "It's extremely promising to have a vaccine that seems to stimulate T cell activity in KRAS-driven tumours – these are generally 'immune cold', so therapies which stimulate immune responses in this group of patients are much needed. 'Many patients have these KRAS mutations, so an off-the-shelf vaccine could benefit lots of people – it saves the cost and time required to make a personalised vaccine. 'However, it's a bit early to definitively tell whether this will work to prevent cancer relapse in this group of patients who have had all disease removed at surgery - larger studies will be needed. "A bigger challenge is to see if the activated immune system could also work against established tumours, which have many ways to avoid immune attack and prevent immune cells from entering.'
The Sun
an hour ago
- The Sun
‘Remarkable' new vaccine shown to slow down world's deadliest cancer in move to ‘beat cancer for everyone'
THOUSANDS of Brits with cancer have been given fresh hope as a new jab could slow down the disease and boost survival. The vaccine, described as "remarkable" by scientists, has shown promising results in the fight against one of the deadliest forms of the disease - pancreatic cancer. Early trials have proven the jab's ability to supercharge the immune system, enabling it to attack cancer cells and potentially prolong life for patients. More trials are now underway among a larger group of pancreatic and bowel cancer patients, as experts warn it is "too early" to say whether the jab will work at scale. Pancreatic cancer, which affects around 10,000 Brits each year, is the deadliest cancer in the world. And only about seven out of 100 of them will survive it for five years or more, according to Cancer Research UK. This is partly because it shows no symptoms until it has already spread to other parts of the body, making it incredibly hard to treat. While surgery, chemotherapy and radiation can help extend life, they rarely offer a cure. But researchers are now optimistic that this new vaccine could change that, providing a vital new treatment option other therapies fall short. 'Our results show that in the group of patients who had profound immune responses 68 per cent) we saw longer survival than we have expected in this cancer,' said Dr Zev Wainberg, study lead from the University of California, Los Angeles. 'Quite a remarkable finding to occur in a phase 1 trial.' The jab targets a mutated gene called KRAS, which is found in many pancreatic and bowel cancers. I'm a doctor, NEVER ignore these pancreatic cancer symptoms It's a type of immunotherapy vaccine designed to improve the immune system's ability to fight cancer by delivering the vaccine directly to the lymph nodes, which play a crucial role in immune defence. In the phase 1 trial, 20 pancreatic cancer patients and five bowel cancer patients received the vaccine. After 20 months, 68 per cent of patients developed strong immune responses. On average, the pancreatic cancer patients survived around two years and five months after receiving the vaccine, according to the study published in Nature Medicine. 'Patients with the strongest immune responses lived longer and stayed cancer-free for more than 15 months,' Dr Zev added. While some cancer jabs are personalised to each patient, this jab, ELI-002 2P, has a single version which can be given to all patients. This "off-the-shelf" version means that it can be manufactured in bulk and given more rapidly. Dr Chris Macdonald, head of research at Pancreatic Cancer UK, said: 'This study is a big step forward in treating pancreatic cancer. "The 'off-the-shelf' vaccine approach is quicker, cheaper, and could help many more people.' The study has already led to a phase 2 trial with 144 pancreatic and bowel cancer patients, with results expected in the coming months. Dr Dani Edmunds, research information manager at Cancer Research UK, added: "Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat. "Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer. "The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment. "These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination. "Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine. "More research is needed to understand why some people benefit from the vaccine while others don't so that we can make sure we're beating cancer for everyone." Dr Magnus Dillon, an oncologist at The Royal Marsden NHS Foundation Trust, said: "It's extremely promising to have a vaccine that seems to stimulate T cell activity in KRAS-driven tumours – these are generally 'immune cold', so therapies which stimulate immune responses in this group of patients are much needed. 'Many patients have these KRAS mutations, so an off-the-shelf vaccine could benefit lots of people – it saves the cost and time required to make a personalised vaccine. 'However, it's a bit early to definitively tell whether this will work to prevent cancer relapse in this group of patients who have had all disease removed at surgery - larger studies will be needed. "A bigger challenge is to see if the activated immune system could also work against established tumours, which have many ways to avoid immune attack and prevent immune cells from entering.'
Daily Mail
3 hours ago
- Daily Mail
Faux-zempic danger: How to tell if YOUR jab is a convincing fake - as TV star reveals near death experience after 'horror' injection
Health officials have issued an urgent warning over dangerous fake weight loss drugs after an influencer nearly died from injecting what she called a 'syringe of horrors.' Celebrity Big Brother star Aisleyne Horgan-Wallace, 46, said she bought the budget weight loss jab via WhatsApp after gaining two stone following a period of emotional eating and mental health struggles. Instead of helping her slim down, the counterfeit Ozempic triggered severe side effects including extreme fatigue, vomiting and diarrhoea. 'I got added to a WhatsApp group where girls talk about what they want to have done—lip filler and things—and someone on there was offering Ozempic,' she said. 'For the first month I felt fine, even energetic and I could see that I was already losing a bit of weight. 'But then I took the second month's [dose] and I came so close to death. 'For three days I thought I was going to die. I was in bed literally comatosed. I'd wake up, roll over and vomit into a bag. 'At one point, I had three bags of vomit by my bedside. I couldn't even walk the two steps to the toilet, I had to crawl and drag myself.' 'Then, I started losing my vision. My eyes were going blurry and I couldn't see. I had no idea what was going to happen to me,' she added, speaking to The Sun. 'I wish I never, ever took the first month's supply or even heard about this drug,' she added. 'It was a syringe of horrors, that's all I know. The chemicals must have been wrong.' The popularity of blockbuster weight loss jabs, which also include Wegovy and Mounjaro, has seen demand overtake supply, fuelling the sale of convincing counterfeit versions that claim to contain the active ingredients semaglutide or tirzepatide. The injections were originally intended for people with type 2 diabetes to help control blood sugar levels but are now offered to those with obesity to aid weight loss. While legitimate versions can cause a range of side effects—including pancreatitis, gut issues and even hair loss—experts warn the dangers of counterfeit drugs are far greater. According to officials, knock-off jabs often contain the hormone insulin, which can trigger heart palpitations, life-threatening seizures and hypoglycaemic shock, where blood sugar levels drop dangerously low. They stress that the only way to be sure a weight loss pen is genuine is to obtain it from a registered pharmacy with a prescription from a healthcare professional. Currently, UK law forbids the sale of such drugs without a prescription and prohibits the promotion of any prescription medication. Offenders can face a fine and up to two years in prison. Novo Nordisk, the pharmaceutical company that manufactures Ozempic and WeGovy, has warned that the sale of counterfeit injections in the UK is a 'critical issue' that poses a direct danger to health. Anne Devaud, the company's head of product security, told The Sun that the best way to stop the spread of fake jabs is for everyone to remain vigilant. She said: 'We need to continue to develop awareness — because everybody has a responsibility. 'If patients are more vigilant, ordering less online and we are collaborating with authorities and authorities are reinforcing regulation to avoid any illicit compounding to enter the country, I'm confident that with this combined effort, we may really make a difference.' The company has urged anyone who believes they may have purchased a counterfeit product not to use it and to report it to the Medicines and Healthcare products Regulatory Agency (MHRA). Andy Morling, head of the MHRA's criminal enforcement unit, told the Daily Mail: 'If you buy medicines from unverified sources, there is no guarantee the product is safe or effective. 'They may even be contaminated with toxins that could cause real harm and leave you hospitalised.' He added: 'Remember [weight loss jabs] are not cosmetic treatments—they are powerful medicines that can only be legally and safely dispensed against a prescription issued by a healthcare professional.' Mr Morling said counterfeit drugs remain rare in the UK, but warned that the market for fake weight loss jabs persists. He said to be vigilant for 'DIY kits' that include the active ingredient in powdered form alongside syringes. The Daily Mail has previously highlighted the case of a mother who was left comatose and almost died after buying a weight loss jab illegally sold online. Despite the serious health risks, social media platforms remain awash with dealers exploiting the lucrative black market, selling the jabs for a fraction of the cost of legitimate products, which can be up to £200. Experts warn many of these fake slimming jabs do not even contain the active ingredients designed to dampen hunger signals. Instead, they are often just insulin pens repackaged to look like the blockbuster drugs. It comes as pharmacists have warned of potential shortages caused by booming demand for weight loss medication—a situation experts say could push more people into buying potentially dangerous jabs online. The National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies, said last month that the current level of demand is unsustainable. GPs in the UK are now allowed to prescribe the drugs, collectively known as GLP-1s in a bid to tackle the nation's obesity crisis—with an estimated 1.5million people suspected to be on the jabs via the NHS or private clinics. In the warning, NPA chairman Olivier Picard said: ''Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate from those who want it. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Under NHS guidelines only patients who have a body mass index (BMI) of over 35, or a BMI of 30 and at least one weight related health problem like high blood pressure, should be prescribed Wegovy.
